OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY OR TARGETED THERAPY FOR NSCLC

F. Hoffmann- La Roche Ltd.0 个研究点目标入组 12 人开始时间: 2015年3月5日最近更新: 2019年2月28日

适应症

试验速览

暂无简介。

•- Age >/= 18 years
•- ECOG performance status (PS) 0 - 1
•- Histologically confirmed squamous NSCLC patients
•- Locally advanced or metastatic (stage IIIB or IV) squamous NSCLC
•- No prior systemic chemotherapy, targeted therapy for metastatic NSCLC
•- Evidence of at least one radiologically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
•- Adequate hematological, liver and renal function
•- Use of highly effective contraception
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 18

•- Concurrent therapy with any other investigational drug
•- History or clinical evidence of central nervous system (CNS) primary tumors or metastases
•- Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus and/or significant cardiovascular disease or uncontrolled infection
•- Any other diseases, metabolic dysfunction, a physical examination finding or a clinical laboratory finding, giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
•- Major surgery or significant traumatic injury < 28 days prior to the first study treatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
•- Pregnant or breast-feeding women
•- History of other malignancies that could affect compliance with protocol or interpretation of results. Patients with malignancies diagnosed more than five years prior to study day one, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer are generally eligible

发起方